Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9434794 | 0.87 | LCK (0.72) | LCKMAOBMAOAALOX5CCNB2 | |
| SCHEMBL9434803 | 0.87 | LCK (0.72) | LCKMAOBMAOAALOX5CCNB2 | |
| SCHEMBL28441803 | 0.86 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP19A1LCKMAOB | |
| SCHEMBL11896472 | 0.84 | LCK (0.64) | CYP1A2CYP1A1CYP19A1LCKMAOB | |
| SCHEMBL14419745 | 0.84 | LCK (0.64) | CYP1A2CYP1A1CYP19A1LCKMAOB | |
| SCHEMBL24633372 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP1A1CYP19A1LCKMAOB | |
| SCHEMBL3650797 | 0.83 | LCK (0.77) | CYP1A2CYP1A1CYP19A1LCKMAOB | |
| SCHEMBL6308482 | 0.83 | LCK (0.77) | CYP1A2CYP1A1CYP19A1LCKMAOB | |
| SCHEMBL3650792 | 0.83 | LCK (0.77) | CYP1A2CYP1A1CYP19A1LCKMAOB | |
| SCHEMBL19728207 | 0.82 | CYP1A1 (0.68) | CYP1A2CYP1A1CYP19A1LCKMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322654-A1 | CANNABINOID DERIVATIVES AND THEIR USE | DEMEETRA AGBIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230248748-A1 | CANNABINOID DERIVATIVES AND THEIR USE | DEMEETRA AGBIO, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230059087-A1 | CANNABIDIOL DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-2023015253-A1 | CANNABINOID DERIVATIVES AND THEIR USE | DEMEETRA AGBIO, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4089084-A1 | CANNABIDIOL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248748-A1 | CANNABINOID DERIVATIVES AND THEIR USE | CNR1, CNR2, FAAH | CYP1A2 602/4885CYP1A1 440/4885CYP19A1 2362/4885 |
| US-20230322654-A1 | CANNABINOID DERIVATIVES AND THEIR USE | CNR1, CNR2, FAAH | CYP1A2 602/4885CYP1A1 440/4885CYP19A1 2362/4885 |
| US-20230059087-A1 | CANNABIDIOL DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF | CNR1, CNR2, UGT2B7 | CYP1A2 20/4885CYP1A1 49/4885CYP19A1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.